Now a new study from researchers at Drexel University’s College of Medicine, and additional colleagues from the NationalInstitute of Allergy and Infectious Diseases (NIAID)-funded national “IMmunoPhenotyping Assessment in a COVID-19 Cohort” (IMPACC), gives clinical providers insights to help patients anticipate what they may or may not experience down the road with the disease. It also gives providers more confidence when they set out a care plan for hospitalized patients aimed to help prevent long COVID, such as determining which patients need antivirals early after disease onset.